Isodiol International Inc. Executes Definitive Agreement to Acquire 100% of C3 Global Biosciences™
December 8, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a definitive agreement with C3 Global Biosciences™ (C3GBS), a cause-driven organization committed to developing sustainable…
Read MoreISODIOL INTERNATIONAL INC. TO PRESENT, EXHIBIT AT 25TH ANNUAL AMERICAN ACADEMY OF ANTI-AGING MEDICINE WORLD CONGRESS
Dr. Ronald Aung-Din to discuss power of patented Direct Effects Technology™ combined with CBD and its effect on neuropsychiatric disorders DECEMBER 7, 2017 – LAS VEGAS – Isodiol International Inc. (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that…
Read MoreIsodiol International Inc. Announces Appointment of Dr. Ronald Aung-Din as an Advisor, Closes Strategic Financing
November 29, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce the appointment of Dr. Ronald Aung-Din as a Medical, Science and Development Advisor to the Company. Dr. Aung-Din,…
Read MoreIsodiol International Inc Signs Binding Agreement to Acquire 100% of C3 Global Biosciences
November 24, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a binding agreement to acquire 100% of C3 Global Biosciences (C3GBS), a cause-driven…
Read MoreIsodiol International Inc. Signs Definitive Agreement to Acquire Bradley’s Bioscience Inc., and Closes Strategic Financing
November 22, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a definitive agreement in connection with its previously announced Letter of Intent (LOI)…
Read MoreIsodiol News: Isodiol International Inc. Upgrades to OTCQB
November 21, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that Isodiol’s common shares have been approved for trading on the OTCQB Venture Market in the United States. The trading…
Read MoreIsodiol International Acquires IsoDerm
November 17, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) A global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that it has acquired international licensing rights for IsoDerm™ as well as five other proprietary pharmaceutical compounds to be delivered…
Read MoreISODIOL INTERNATIONAL SIGNS LETTER OF INTENT TO ACQUIRE BRADLEY’S BIOSCIENCE
ISODIOL INTERNATIONAL INC. SIGNS LETTER OF INTENT TO ACQUIRE BRADLEY’S BIOSCIENCE INC., EXPANDS INTO VAPING AND THC ADDITIVE INDUSTRIES November 9, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to…
Read MoreIsodiol International Inc. Announces Update on Commercialization Strategy for Pot-O-Coffee Brand, Acquisition of Culinary Coffee
November 1, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has committed distribution licenses for its Pot-O-Coffee brands in the states of Oregon, Washington, Illinois and…
Read MoreIsodiol International Inc. Provides Investor Update
October 18, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, reports the Canadian Securities Exchange (CSE) will continue to welcome companies with links to the US cannabis market, a contrast to the statement…
Read MoreIsodiol International Inc to Implement Blockchain Technology for Payment Processing
October 17, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that it is in the final stages of advanced due diligence for implementing Blockchain technology for payment processing. The company…
Read MoreIsodiol International Provides Corporate Update
October 13, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announces fiscal 2018 Q2 revenues of it’s wholly owned subsidiary ISO International LLC of, $4.07 million USD ($5.1 million CDN) compared to fiscal 2018…
Read MoreIsodiol International to Present at New West Summit Cannabis Conference in Oakland
October 10, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today Marvin Washington, former NFL athlete and brand ambassador for Isodiol, will be speaking at the New West Summit Cannabis Conference being held at…
Read MoreIsodiol International Inc. Commences Approval Process to Bring Isodiol to Chilean Market
October 4, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, is pleased to announce that the Company has officially initiated the approval process to begin exporting its flagship product, Isoderm to Chile. Marcos Agramont,…
Read MoreIsodiol International Inc. Announces Formation of IsoLabs, Plans to Expand With THC Product Offerings
September 28, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce the formation of IsoLabs International, a new division that will focus in the licensed medical marijuana markets in both North America…
Read More